Format

Send to

Choose Destination
Int J Cancer. 2018 May 1;142(9):1738-1747. doi: 10.1002/ijc.31147. Epub 2017 Nov 27.

Chimeric antigen receptor transduced T cells: Tuning up for the next generation.

Author information

1
Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
2
German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Center for Tumor Diseases (NCT), Heidelberg, Germany.

Abstract

Chimeric antigen receptor (CAR) T cell therapy has recently achieved impressive clinical outcome in patients with CD19-positive hematologic malignancies. Extrapolation of CAR T cell treatment to solid tumors, however, has not yet yielded similar results. This might be due to intrinsic causes, e.g. insufficient CAR T cell activation or CAR toxicity as well as extrinsic factors displaying an unfavorable tumor environment for CAR T cells by raising physical and chemical barriers. In this review, we discuss the advantages as well as major obstacles of CAR T cell therapy, particularly in the context of solid tumors, and focus on efforts and novel strategies in CAR T cell development.

KEYWORDS:

CAR T cell design; CAR T cells; chimeric antigen receptor (CAR); clinical CAR trials; hematologic malignancies; immunotherapy; solid tumors

PMID:
29119551
DOI:
10.1002/ijc.31147
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center